Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Déjou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou JF, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N.

Cell Rep. 2019 May 21;27(8):2411-2425.e9. doi: 10.1016/j.celrep.2019.04.091.

2.

The flame-not the ashes: achievements and heritage of a passionate analytical chemist.

Gros L, Knepper TP.

Anal Bioanal Chem. 2019 Apr;411(10):1927-1933. doi: 10.1007/s00216-019-01647-y. Epub 2019 Feb 27.

PMID:
30810793
3.

Targeting of epigenetic regulators in neuroblastoma.

Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R, Roma J, Toledo JS, Gallego S, Segura MF.

Exp Mol Med. 2018 Apr 27;50(4):51. doi: 10.1038/s12276-018-0077-2. Review.

4.

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Barjon C, Michaud HA, Fages A, Dejou C, Zampieri A, They L, Gennetier A, Sanchez F, Gros L, Eliaou JF, Bonnefoy N, Lafont V.

Oncoimmunology. 2017 Oct 4;7(1):e1379642. doi: 10.1080/2162402X.2017.1379642. eCollection 2017.

5.

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.

Hammam K, Saez-Ayala M, Rebuffet E, Gros L, Lopez S, Hajem B, Humbert M, Baudelet E, Audebert S, Betzi S, Lugari A, Combes S, Letard S, Casteran N, Mansfield C, Moussy A, De Sepulveda P, Morelli X, Dubreuil P.

Nat Commun. 2017 Nov 10;8(1):1420. doi: 10.1038/s41467-017-01582-5.

6.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

7.

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.

Trias E, Ibarburu S, Barreto-Núñez R, Babdor J, Maciel TT, Guillo M, Gros L, Dubreuil P, Díaz-Amarilla P, Cassina P, Martínez-Palma L, Moura IC, Beckman JS, Hermine O, Barbeito L.

J Neuroinflammation. 2016 Jul 11;13(1):177. doi: 10.1186/s12974-016-0620-9.

8.

Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.

Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L.

Oncoimmunology. 2014 Dec 13;3(9):e955684. eCollection 2014 Oct. Review.

9.

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response.

Lafont V, Sanchez F, Laprevotte E, Michaud HA, Gros L, Eliaou JF, Bonnefoy N.

Front Immunol. 2014 Dec 8;5:622. doi: 10.3389/fimmu.2014.00622. eCollection 2014. Review.

10.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

11.

Aberrant repair initiated by mismatch-specific thymine-DNA glycosylases provides a mechanism for the mutational bias observed in CpG islands.

Talhaoui I, Couve S, Gros L, Ishchenko AA, Matkarimov B, Saparbaev MK.

Nucleic Acids Res. 2014 Jun;42(10):6300-13. doi: 10.1093/nar/gku246. Epub 2014 Apr 1.

12.

The role of leptin in diencephalic syndrome.

Velasco P, Clemente M, Lorite R, Ventura MC, Gros L, Sanchez de Toledo J, Gallego S.

Pediatrics. 2014 Jan;133(1):e263-6. doi: 10.1542/peds.2012-3196. Epub 2013 Dec 23.

PMID:
24366994
13.

[Vaccine-like effects of antiviral monoclonal antibodies: a novel therapeutic perspective?].

Pelegrin M, Gros L, Piechaczyk M.

Med Sci (Paris). 2013 May;29(5):457-60. doi: 10.1051/medsci/2013295005. Epub 2013 May 28. French. No abstract available.

14.

Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies.

Nasser R, Pelegrin M, Plays M, Gros L, Piechaczyk M.

Blood. 2013 Feb 14;121(7):1102-11. doi: 10.1182/blood-2012-06-432153. Epub 2012 Dec 20.

PMID:
23264590
15.

Evaluation of three novel azasterols against Toxoplasma gondii.

Martins-Duarte ES, Lemgruber L, Lorente SO, Gros L, Magaraci F, Gilbert IH, de Souza W, Vommaro RC.

Vet Parasitol. 2011 Apr 19;177(1-2):157-61. doi: 10.1016/j.vetpar.2010.11.034. Epub 2010 Dec 1.

16.

Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.

Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P.

J Biol Chem. 2011 Feb 25;286(8):5956-66. doi: 10.1074/jbc.M110.182642. Epub 2010 Dec 6.

17.

Acetazolamide-based fungal chitinase inhibitors.

Schüttelkopf AW, Gros L, Blair DE, Frearson JA, van Aalten DM, Gilbert IH.

Bioorg Med Chem. 2010 Dec 1;18(23):8334-40. doi: 10.1016/j.bmc.2010.09.062. Epub 2010 Oct 8.

18.

Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, Gros L.

J Virol. 2010 Oct;84(19):10169-81. doi: 10.1128/JVI.00568-10. Epub 2010 Jul 7.

19.

A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.

Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, Jacquet C, Hernandez J, Piechaczyk M, Pelegrin M.

PLoS Pathog. 2010 Jun 10;6(6):e1000948. doi: 10.1371/journal.ppat.1000948.

20.

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.

PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.

21.

Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children.

Muñoz A, Alfaro J, Pardo N, García-Miguel P, Quintero V, Gros L, Melero C, Antuña MJ, Ocete G, de Las Heras J, Ruiz del Portal M, Huguet R, Maldonado MS.

Clin Transl Oncol. 2009 Jun;11(6):387-92.

PMID:
19531454
22.

Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab.

Gallego S, Llort A, Gros L, Sanchez de Toledo J Jr, Bueno J, Moreno A, Nieto J, Sanchez de Toledo J.

Pediatr Transplant. 2010 Feb;14(1):61-6. doi: 10.1111/j.1399-3046.2009.01181.x. Epub 2009 Mar 31.

PMID:
19344338
23.

Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites.

Baliani A, Peal V, Gros L, Brun R, Kaiser M, Barrett MP, Gilbert IH.

Org Biomol Chem. 2009 Mar 21;7(6):1154-66. doi: 10.1039/b813394h. Epub 2009 Jan 28.

PMID:
19262935
24.

The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.

Perfettini JL, Nardacci R, Séror C, Bourouba M, Subra F, Gros L, Manic G, Amendola A, Masdehors P, Rosselli F, Ojcius DM, Auclair C, de Thé H, Gougeon ML, Piacentini M, Kroemer G.

Cell Death Differ. 2009 Feb;16(2):298-311. doi: 10.1038/cdd.2008.158. Epub 2008 Nov 21.

25.

Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia.

Perfettini JL, Nardacci R, Bourouba M, Subra F, Gros L, Séror C, Manic G, Rosselli F, Amendola A, Masdehors P, Chessa L, Novelli G, Ojcius DM, Siwicki JK, Chechlinska M, Auclair C, Regueiro JR, de Thé H, Gougeon ML, Piacentini M, Kroemer G.

PLoS One. 2008 Jun 18;3(6):e2458. doi: 10.1371/journal.pone.0002458.

26.

Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.

Gros L, Pelegrin M, Michaud HA, Bianco S, Hernandez J, Jacquet C, Piechaczyk M.

J Virol. 2008 Feb;82(3):1339-49. Epub 2007 Nov 21.

27.

Quinuclidine derivatives as potential antiparasitics.

Cammerer SB, Jimenez C, Jones S, Gros L, Lorente SO, Rodrigues C, Rodrigues JC, Caldera A, Ruiz Perez LM, da Souza W, Kaiser M, Brun R, Urbina JA, Gonzalez Pacanowska D, Gilbert IH.

Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61. Epub 2007 Aug 20.

28.

Characterization of prmt7alpha and beta isozymes from Chinese hamster cells sensitive and resistant to topoisomerase II inhibitors.

Gros L, Renodon-Cornière A, de Saint Vincent BR, Feder M, Bujnicki JM, Jacquemin-Sablon A.

Biochim Biophys Acta. 2006 Nov;1760(11):1646-56. Epub 2006 Sep 14.

PMID:
17049166
29.
30.

Evaluation of azasterols as anti-parasitics.

Gros L, Lorente SO, Jimenez CJ, Yardley V, Rattray L, Wharton H, Little S, Croft SL, Ruiz-Perez LM, Gonzalez-Pacanowska D, Gilbert IH.

J Med Chem. 2006 Oct 5;49(20):6094-103.

PMID:
17004723
31.

Major oxidative products of cytosine are substrates for the nucleotide incision repair pathway.

Daviet S, Couvé-Privat S, Gros L, Shinozuka K, Ide H, Saparbaev M, Ishchenko AA.

DNA Repair (Amst). 2007 Jan 4;6(1):8-18. Epub 2006 Sep 15.

PMID:
16978929
32.

New azasterols against Trypanosoma brucei: role of 24-sterol methyltransferase in inhibitor action.

Gros L, Castillo-Acosta VM, Jiménez Jiménez C, Sealey-Cardona M, Vargas S, Manuel Estévez A, Yardley V, Rattray L, Croft SL, Ruiz-Perez LM, Urbina JA, Gilbert IH, González-Pacanowska D.

Antimicrob Agents Chemother. 2006 Aug;50(8):2595-601.

33.
34.

Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.

Gallego S, Llort A, Roma J, Sabado C, Gros L, de Toledo JS.

J Cancer Res Clin Oncol. 2006 Jun;132(6):356-62. Epub 2006 Jan 25.

PMID:
16435141
35.

Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.

Parareda A, Gallego S, Roma J, Llort A, Sábado C, Gros L, De Toledo JS.

Oncol Rep. 2005 Oct;14(4):1021-7.

PMID:
16142367
36.

Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics.

Lorente SO, Jimenez CJ, Gros L, Yardley V, de Luca-Fradley K, Croft SL, A Urbina J, Ruiz-Perez LM, Pacanowska DG, Gilbert IH.

Bioorg Med Chem. 2005 Sep 15;13(18):5435-53.

PMID:
16046134
37.

Wilhelm Fresenius 1913-2004.

Gros L.

Anal Bioanal Chem. 2005 Aug;382(8):1730-2. No abstract available.

PMID:
15940447
38.

Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Gros L, Dreja H, Fiser AL, Plays M, Pelegrin M, Piechaczyk M.

J Virol. 2005 May;79(10):6272-80.

39.

Monoclonal antibody-based genetic immunotherapy.

Pelegrin M, Gros L, Dreja H, Piechaczyk M.

Curr Gene Ther. 2004 Sep;4(3):347-56. Review.

PMID:
15384948
40.

Are endogenous clustered DNA damages induced in human cells?

Bennett PV, Cintron NS, Gros L, Laval J, Sutherland BM.

Free Radic Biol Med. 2004 Aug 15;37(4):488-99.

PMID:
15256220
41.

Hijacking of the human alkyl-N-purine-DNA glycosylase by 3,N4-ethenocytosine, a lipid peroxidation-induced DNA adduct.

Gros L, Maksimenko AV, Privezentzev CV, Laval J, Saparbaev MK.

J Biol Chem. 2004 Apr 23;279(17):17723-30. Epub 2004 Feb 2.

42.

The major human AP endonuclease (Ape1) is involved in the nucleotide incision repair pathway.

Gros L, Ishchenko AA, Ide H, Elder RH, Saparbaev MK.

Nucleic Acids Res. 2004 Jan 2;32(1):73-81. Print 2004.

43.

Enzymology of repair of etheno-adducts.

Gros L, Ishchenko AA, Saparbaev M.

Mutat Res. 2003 Oct 29;531(1-2):219-29. Review.

PMID:
14637257
44.

Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor.

Dreja H, Gros L, Villard S, Bachrach E, Oates A, Granier C, Chardes T, Mani JC, Piechaczyk M, Pelegrin M.

J Virol. 2003 Oct;77(20):10984-93.

45.

Inhibition of ATP-sensitive K+ channels by substituted benzo[c]quinolizinium CFTR activators.

Prost A, Dérand R, Gros L, Becq F, Vivaudou M.

Biochem Pharmacol. 2003 Aug 1;66(3):425-30.

PMID:
12907241
46.

Characterization of two independent amino acid substitutions that disrupt the DNA repair functions of the yeast Apn1.

Jilani A, Vongsamphanh R, Leduc A, Gros L, Saparbaev M, Ramotar D.

Biochemistry. 2003 Jun 3;42(21):6436-45.

PMID:
12767225
47.

Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents.

Gros L, Delaporte C, Frey S, Decesse J, de Saint-Vincent BR, Cavarec L, Dubart A, Gudkov AV, Jacquemin-Sablon A.

Cancer Res. 2003 Jan 1;63(1):164-71.

48.

Enzymology of the repair of free radicals-induced DNA damage.

Gros L, Saparbaev MK, Laval J.

Oncogene. 2002 Dec 16;21(58):8905-25. Review.

49.

Characterization of two novel forms of the rat sulphonylurea receptor SUR1A2 and SUR1BDelta31.

Gros L, Trapp S, Dabrowski M, Ashcroft FM, Bataille D, Blache P.

Br J Pharmacol. 2002 Sep;137(1):98-106.

50.

Localization of alpha-endosulphine in pancreatic somatostatin delta cells and expression during rat pancreas development.

Gros L, Bréant B, Duchene B, Leroy C, Fauconnier G, Bataille D, Virsolvy A.

Diabetologia. 2002 May;45(5):703-10. Epub 2002 Apr 3.

PMID:
12107751

Supplemental Content

Support Center